11 completed, 4 recruiting, 4 unknown, 3 terminated. 25 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 11, Recruiting 4, Unknown 4, Terminated 3, Withdrawn 2, Not yet recruiting 1 |
| Phase 1 | 4 | Recruiting 3, Terminated 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
Follow Intestinal Polyposis: new trials by email Literature Review of Intestinal Polyposis trials Research Report on Intestinal Polyposis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis Rapamycin - Familial Adenomatous Polyposis | Phase 2 | Not yet recruiting | University Hospital, Toulouse | 25 | 2026-09-01 | 2026-05-08 |
| An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis Biopsy Procedure, Biospecimen Collection, EP2/EP4 Antagonist TPST-1495 - Colorectal Carcinoma, Familial Adenomatous Polyposis | Phase 2 | Recruiting | National Cancer Institute (NCI) | 38 | 2026-03-31 | 2026-09-14 |
| Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma Tegavivint - Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Recruiting | HonorHealth Research Institute | 126 | 2026-02-17 | 2026-03-11 |
| Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) REC-4881, Placebo - Familial Adenomatous Polyposis | Phase 1 / Phase 2 | Recruiting | Recursion Pharmaceuticals Inc. | 67 | 2023-07-10 | 2026-06-05 |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors FOG-001, mFOLFOX-6, Nivolumab - Cancer, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Parabilis Medicines, Inc. | 619 | 2023-05-23 | 2026-10-07 |
| Testing Obeticholic Acid for Familial Adenomatous Polyposis Biopsy Procedure, Biospecimen Collection, Gastrointestinal Endoscopy - Attenuated Familial Adenomatous Polyposis, Colorectal Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 15 | 2023-01-19 | 2026-05-14 |
| The CHAMP-study: The CHemopreventive Effect of Lithium in Familial AdenoMatous Polyposis Lithium Carbonate - Familial Adenomatous Polyposis | Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 12 | 2022-06-02 | 2024-10-04 |
| Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance Encapsulated Rapamycin (eRapa) - Familial Adenomatous Polyposis | Phase 2 | Completed | Rapamycin Holdings Inc. | 30 | 2021-01-18 | 2026-10-22 |
| Niclosamide for Familial Adenomatous Polyposis Niclosamide, placebo - Familial Adenomatous Polyposis | Phase 2 | Unknown | Yonsei University | 72 | 2020-02-14 | 2020-03-05 |
| Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer Erlotinib, Erlotinib Hydrochloride - Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis | Phase 2 | Completed | National Cancer Institute (NCI) | 46 | 2017-10-27 | 2022-07-26 |
| Sirolimus and Familial Adenomatous Polyposis (FAP) Sirolimus - Adenomatous Polyposis Coli | Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 4 | 2017-10-03 | 2024-10-24 |
| Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous Polyposis. Wholistic Turmeric capsules, Placebo - Familial Adenomatous Polyposis, FAP | Phase 2 | Unknown | Tel-Aviv Sourasky Medical Center | 40 | 2017-04-01 | 2017-02-23 |
| The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study Metformin, Placebo - Familial Adenomatous Polyposis | Phase 2 | Completed | Yonsei University | 34 | 2013-02-15 | 2021-09-20 |
| Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome Everolimus - Peutz-Jeghers Syndrome, Neoplastic Processes | Phase 2 | Withdrawn | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2010-10-01 | 2015-04-22 | |
| Curcumin in Treating Patients With Familial Adenomatous Polyposis Curcumin, Laboratory Biomarker Analysis, Placebo - Familial Adenomatous Polyposis | Phase 2 | Completed | National Cancer Institute (NCI) | 44 | 2010-10-01 | 2017-09-29 |
| A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients Erlotinib, Sulindac, Placebo A - Adenomatous Polyposis Coli | Phase 2 | Completed | University of Utah | 92 | 2010-04-01 | 2016-06-17 |
| Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Celecoxib, Ursodeoxycholic acid, Placebo - Familial Adenomatous Polyposis, Duodenal Neoplasms | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 37 | 2009-05-01 | 2013-05-16 |
| Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome Everolimus - Peutz-Jeghers Syndrome | Phase 2 | Terminated | University of Utah | 3 | 2008-11-01 | 2024-09-19 |
| Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma Synthetic Human Secretin - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 4 | 2006-11-01 | 2013-06-24 |
| Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA Eicosapentanoic Acid (EPA), Endoscopy, Biopsies taken - Familial Adenomatous Polyposis Coli, FAP | Phase 2 / Phase 3 | Completed | S.L.A. Pharma AG | 58 | 2006-11-01 | 2014-08-22 |
Showing 20 of 25. Sign in to see all of them.
Adenomatous Polyposis Coli (22) · Colorectal Neoplasms (6) · Neoplasms (3) · Peutz-Jeghers Syndrome (3) · Polyps (3) · Adenoma (2) · Attenuated familial adenomatous polyposis (2) · Duodenal Neoplasms (2) · Neoplasm Metastasis (2) · Adenomatous Polyps (1) · Carcinoma, Hepatocellular (1) · Craniopharyngioma (1) · Desmoid Tumors (1) · Diabetes Mellitus (1) · Digestive System Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (25) · Digestive System Diseases (24) · Gastrointestinal Diseases (24) · Genetic Diseases, Inborn (24) · Intestinal Diseases (24) · Neoplastic Syndromes, Hereditary (24) · Neoplasms by Site (23) · Colonic Diseases (22) · Digestive System Neoplasms (22) · Neoplasms (22) · Neoplasms by Histologic Type (22) · Neoplasms, Glandular and Epithelial (22) · Adenomatous Polyps (21) · Gastrointestinal Neoplasms (21)
Celecoxib (3) · Biopsy (2) · Curcumin (2) · Endoscopy, Gastrointestinal (2) · Erlotinib Hydrochloride (2) · Everolimus (2) · Sirolimus (2) · Specimen Handling (2) · Sulindac (2) · Ursodeoxycholic Acid (2) · Bevacizumab (1) · Eflornithine (1) · Eicosapentaenoic Acid (1) · Endoscopy (1) · Endoscopy, Digestive System (1)
National Cancer Institute (NCI) (5) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (3) · Radboud University Medical Center (2) · University of Utah (2) · Yonsei University (2) · Assistance Publique - Hôpitaux de Paris (1) · HonorHealth Research Institute (1) · Johns Hopkins University (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Parabilis Medicines, Inc. (1) · Rapamycin Holdings Inc. (1) · Recursion Pharmaceuticals Inc. (1) · S.L.A. Pharma AG (1) · Tel-Aviv Sourasky Medical Center (1)
United States (13) · Netherlands (5) · Puerto Rico (3) · France (2) · South Korea (2) · Australia (1) · United Kingdom (1)
Niloy J Samadder (2) · Benjamin Oshrine (1) · Bjorn WH van Heumen, MD (1) · Eduardo Vilar-Sanchez (1) · Ellen Kampman, Ph D (1) · Emmanuel Mas, Pr (1) · Evelien Dekker, MD, PhD (1) · Fokko M Nagengast, MD, Ph D (1) · Fokko M Nagengast, PhD (1) · Francis Giardiello (1) · Francis M Giardiello, M.D. (1) · Gary Shangold, MD (1) · Heinz-Josef Klumpen, MD (1) · Imad Shureiqi, MD (1) · Naoki Takahashi, M.D. (1)
PMID 37119510, PMID 20348368, PMID 21899713, PMID 23919274, PMID 24245549, PMID 25792707, PMID 27002448, PMID 29371475, PMID 29423501, PMID 29802852, PMID 30012100, PMID 33376109, PMID 33509804, PMID 35636921, PMID 35962368, PMID 39956770
P30CA016672 (2), N01CN00042 (1), P01CA073992 (1), P30CA006973 (1), P30CA014520 (1), P30CA015083 (1), R01CA106577 (1), R01CA134620 (1), UG1CA242596 (1), UG1CA242609 (1), UG1CA242635 (1)